The CheckMate 141 clinical trial demonstrated an advantage of nivolumab over investigator’s choice in terms of survival and short-term health-related quality of life when administered to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

This article reports a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis in patients who received nivolumab compared with those who received investigator’s choice in CheckMate 141.

Our analysis extends previous findings from CheckMate 141 to demonstrate that patients randomized to nivolumab had statistically significant and clinically meaningful gains in Q-TWiST compared with patients randomized to investigator’s choice.